The mechanism of function in the genetic variant in RTEL is yet to be understood, and there are several other plausible genes in the chromosomal area that could be the actual gene with functional effect such as STMN3 suggested by Labreche et al., or DcR3, a gene that has been differentially expressed in glioma and suggested as a therapeutic target by preclinical studies [41,42]. This evidence concerns the gene TNFRSF6B and central nervous system cancer.